Psoriasis&nbsp;&nbsp;&nbsp;

How do you approach managing nausea and GI side effects when initiating methotrexate?

How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?

SLE manifestations include arthralgias and cytopenias which are stable. Previously did well on methotrexate, but developed GI side effects. HCQ is on ...

Are you comfortable utilizing Stelara (ustekinumab) as biologic treatment of psoriasis for patients with a history of severe latex allergy?

Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?

How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?

The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.

How do you approach treating patients who develop psoriasis while on Dupixent?

Do you start/trial them on another biologic or just rely on topical therapies?

How have you incorporated biologics targeting the IL-36 pathway (e.g. Spevigo) into your treatment algorithm for psoriasis?

Do you caution against starting biologics for psoriasis if patient has hepatitis A antibodies?

What topical therapies have you found most effective for managing scalp psoriasis?

Do you use combination therapies such as betamethasone and calcipotriene foam?

Do you wait on initiating biologic therapy for guttate psoriasis?

If so, how long?

What biologic for psoriasis do you prescribe most often in patients with a history of malignancy?

4 Answers available

How do you approach treatment change in patients with psoriasis who have been stable on an IL-17 or IL-23 agent but then begin to have breakthrough skin disease?

Do you first try adding topicals or UV? At what point do you decide to switch biologics and at that point do you try to class switch to a different MO...

How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?

What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?

How have you incorporated new psoriasis therapies such as deucravacitinib and bimekizumab into your hierarchy of psoriasis treatments?

Are there patients that you find respond best to these therapies?

How does the location or type of psoriasis affect your initial biologic choice?

Do you discontinue IL-17A, IL-17A/F, or IL-23 blockade in pregnant patients with psoriasis?

What are the best biologics for a pediatric patient with extensive guttate psoriasis that is poorly controlled on topicals?

Mother's insurance plan has a high deductible and phototherapy is inconvenient (family lives 50 minutes away).

How do you approach patients that develop atopic dermatitis while on biologics for psoriasis?

I have an elderly patient with a history of biopsy-proven psoriasis on IL-17 biologic therapy. She has developed an intense itch without a primary ras...

What lab monitoring and frequency do you recommend in an otherwise healthy young patient on biologics for psoriasis?

With no high-risk exposure do you repeat quant gold?

4 Answers available

Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?

Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?